Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CNR2 | P34972 | 7/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16114842 | 1.00 | MEN1 (0.56) | MEN1KMT2ACNR2POLBCNR1 | |
| SCHEMBL14943683 | 0.89 | MEN1 (0.55) | MEN1KMT2ACNR2POLBCNR1 | |
| SCHEMBL16115275 | 0.87 | CNR2 (0.54) | MEN1KMT2ACNR2POLBCNR1 | |
| SCHEMBL12401203 | 0.87 | MEN1 (0.54) | MEN1KMT2ACNR2POLBCNR1 | |
| SCHEMBL15219609 | 0.87 | MEN1 (0.54) | MEN1KMT2ACNR2POLBCNR1 | |
| SCHEMBL12482254 | 0.86 | POLB (0.54) | MEN1KMT2ACNR2POLBCNR1 | |
| SCHEMBL7478303 | 0.84 | HDAC2 (0.53) | MEN1KMT2ACNR2ALDH1A1HPGD | |
| SCHEMBL19656678 | 0.81 | SMN1; SMN2 (0.61) | KMT2AALDH1A1HPGDHDAC8HDAC6 | |
| SCHEMBL9963921 | 0.80 | CNR2 (0.57) | MEN1KMT2ACNR2POLBCNR1 | |
| SCHEMBL9963918 | 0.80 | CNR2 (0.57) | MEN1KMT2ACNR2POLBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114634955-B | Method for preparing L-tertiary leucine by biological enzyme catalysis and application thereof | 金达威生物技术(江苏)有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-114634955-A | Method for preparing L-tert-leucine through biological enzyme catalysis and application thereof | 金达威生物技术(江苏)有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | viDA Therapeutics (CA) | 2019-06-25 | — | — | US | disclosed |
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2018-03-01 | — | — | US | disclosed |
| US-9605021-B2 | Indoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-03-28 | — | — | US | disclosed |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| CN-102533888-B | Continuous enzymatic method for producing L-tert-leucine | ZHEJIANG JIUZHOU PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-07-15 | — | — | CN | disclosed |
| WO-2014153666-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS, INC. (CA) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014153667-A1 | COSMETIC USES AND METHODS FOR INDOLINE GRANZYME B INHIBITOR COMPOSITIONS | VIDA THERAPEUTICS, INC. (CA) | 2014-10-02 | — | — | WO | disclosed |
| CN-102533888-A | Continuous enzymatic method for producing L-tert-leucine | ZHEJIANG JIUZHOU PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-07-04 | — | — | CN | disclosed |
| US-6180374-B1 | ENANTIOMORPHS; BIOTRANSFORMATION USING ENZYME IN PRESENCE OF AN ALCOHOL OF AN AZLACTONE | CHIROTECH TECHNOLOGY, INC. (GB) | 2001-01-30 | — | — | US | disclosed |
| EP-0726891-B1 | A METHOD FOR PREPARING TERT-LEUCINE AND ANALOGUES THEREOF IN ENANTIOMERIC FORM, AND INTERMEDIATES THEREIN | CHIROTECH TECHNOLOGY LTD (GB) | 1999-02-03 | — | — | EP | disclosed |
| EP-0726891-A1 | A METHOD FOR PREPARING $i(TERT)-LEUCINE AND ANALOGUES THEREOF IN ENANTIOMERIC FORM, AND INTERMEDIATES THEREIN | Chiroscience Limited (GB) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995012573-A1 | A METHOD FOR PREPARING TERT-LEUCINE AND ANALOGUES THEREOF IN ENANTIOMERIC FORM, AND INTERMEDIATES THEREIN | CHIROSCIENCE LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | MEN1 1148/4885KMT2A 4299/4885CNR2 4756/4885 |
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | GZMB, PRF1, CTSB | MEN1 1148/4885KMT2A 4299/4885CNR2 4756/4885 |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | MEN1 1148/4885KMT2A 4299/4885CNR2 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.